Table 1

Demographic characteristics of study participants

Training group


Response to methotrexate

Response to methotrexate + etanercept

Healthy control


Patients

Age

Time to CRM

Patients

Age

Time to CRM

Control

Age

(month)

(month)


1

9

7

1

13

20

1

16

2

16

8

2

3

24

2

18

3*

11

10

3

3

48

3

9

4

7

14

4

6

8

4

11

5

11

12

5

4

18

5

10

6*

6

15

6

5

42

6

11

7

7

32

7

14

15

7

10

8*

11

13

8

9

25

8

10

9

7

36

9

10

30

9

11

10

4

46

10

15

25

10

13

11

11

8

11

11

20

11

13

12

7

15

12

12

24

12

10

13

11

48

13

12

24

13

12

14*

6

9

14

7

11

14

12


Testing group


Response to methotrexate

Response to methotrexate + etanercept

Healthy control


Patients

Age

Time to CRM

Patients

Age

Time to CRM

Control

Age

(month)

(month)


1

12

27

1

9

24

1

12

2

5

12

2

17

10

2

15

3

12

11

3

6

17

3

8

4

14

11

4

7

26

4

9

5

16

11

5

12

26

5

8

6

5

13

6

5

18

6

11

7

4

10

7

6

24

7

15

8

7

17

8

15

16

8

11


*RNA from granulocytes was insufficient for microarray analysis. CRM, clinical remission on medication.

Jiang et al. Arthritis Research & Therapy 2013 15:R100   doi:10.1186/ar4280

Open Data